Company Overview
Snapshot
Founded in January 2021 by Assaf Bivas, KIP Medical operates with 1–10 employees. The company has secured funding across one round from one investor. In May 2025, KIP Medical received seed funding from Pollen Group Israel.
Business overview
KIP Medical specializes in the research and development of innovative plant-derived solutions to address various pathological conditions involving immune system dysregulation. The company focuses on unmet medical needs in enhancing immune system control for disorders such as autoimmune diseases and transplanted organ rejection, as well as conditions caused by inflammation and tissue damage. KIP Medical is currently developing a novel drug aimed at innovating therapies for dry mouth syndrome and other inflammatory conditions, operating within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Drugs Discovery & Development.
Log in to access full profile ›Company Intelligence Q&A
- When was KIP Medical founded?
- KIP Medical was founded in January 2021.
- Who is a co-founder of KIP Medical?
- Assaf Bivas is a co-founder of KIP Medical.
- What is KIP Medical's primary focus?
- KIP Medical focuses on the research and development of plant-derived solutions to treat conditions involving immune system dysregulation, such as autoimmune diseases and inflammation.
- What is KIP Medical's current product development focus?
- KIP Medical is currently focused on developing a novel drug to innovate the therapy of dry mouth syndrome and other inflammatory conditions.
- Which investor participated in KIP Medical's funding round?
- Pollen Group Israel was the sole investor in this round.